跳至主要内容
临床试验/NCT06494072
NCT06494072招募中4 期

Short Versus Standard of Care Antibiotic Duration for Hospitalized Children With Uncomplicated Community-acquired Pneumonia: a Non-inferiority, Randomized Controlled Trial.

Medical College of Wisconsin1 个研究点 分布在 1 个国家目标入组 236 人开始时间: 2024年8月22日最近更新:
适应症
干预措施

试验速览

阶段
4 期
状态
招募中
入组人数
236
试验地点
1
主要终点
Treatment failure rate

研究概览

简要总结

The goal of this open label, randomized, non-inferiority clinical trial is to compare the treatment success of a 5 day antibiotic course versus a standard antibiotic course (usually 7-14 days of antibiotics) in hospitalized children aged 3 months to 18 years, with uncomplicated community acquired pneumonia.

The main questions it aims to answer are:

  • Does a 5 day course work as well as standard (longer) courses of antibiotics for treating community acquired pneumonia in children?
  • Does a 5 day course cause less antibiotic side effects compared to a standard (longer) course of antibiotics in children with community acquired pneumonia?

Participants will

  • be randomly assigned to either receive 5 total days or a total duration decided by the treating physician
  • receive a brief follow up questionnaire regarding clinical symptoms, follow up care/antibiotics, and side effects via phone or email at days 5 and 14 from the start of antibiotics

Researchers will compare the experimental group (receiving 5 days duration) with the control group (standard duration) to see if 5 days is as successful as a standard duration.

详细描述

This is an open label, randomized, non-inferiority clinical trial to determine if a 5-day antibiotic course works as well compared to a standard antibiotic course (usually 7-10 days of antibiotics) in hospitalized children who are aged 3 months to less than 18 years old, with uncomplicated community acquired pneumonia.

We will recruit 150 participants meeting inclusion/exclusion criteria. Participants will be randomized to one of the study groups. In the experimental group, the participant will receive a total antibiotic course of 5 days. In the other group (control group), participants will receive the standard-of-care antibiotic course (the duration will be decided by the primary treating physician in this group). The selection of antibiotic therapy will be made by the treating physician, generally in accordance with the institutional clinical practice guideline on community acquired pneumonia, prior to enrollment in the study. Other medical care, aside from the treatment duration, will be the same and will be guided by the primary treating doctor. The primary treating doctor will also decide when the participant is medically ready for discharge from the hospital.

During the consenting process, a member of the research team will verify the contact numbers or email of the parent(s)/guardian of participant to be used after discharge for follow-up communication. Every participant's parent/guardian will receive a text message/email questionnaire on day 5 and day 14 after the start of antibiotics to assess for clinical improvement, side effect(s) to the antibiotics, recurrence of fever, or need for additional antibiotics or other medical care. Participants parent(s)/guardian will be contacted by phone for additional information if there is concern for a failure or significant medical concern.

The primary objective of this study is to compare the failure rate between a short course (5-days) and standard antibiotic course (usually 7-10 days of antibiotics) of antibiotics in hospitalized children with uncomplicated pneumonia. Failure will be defined as the clinical need for additional antibiotic treatment, emergency department visit or readmission to the hospital for a suspected lower respiratory tract infection within 14 days of treatment initiation.

The secondary objective will compare the rate of adverse drug events between short and long-course durations of antibiotic therapy in children hospitalized for CAP. Adverse drug events include any allergic reaction such as skin rash, itching or other and/or abdominal symptoms such as vomiting, stomach pain and diarrhea.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
3 Months 至 18 Years(Child, Adult)
性别
All
接受健康志愿者

入选标准

  • (ALL of the following must be met):
  • Children aged 3 months to <18 years old
  • Hospitalized in either the acute care or the pediatric intensive care units
  • Clinically diagnosed with uncomplicated bacterial community acquired pneumonia (as determined by the treating physician)
  • Radiological findings suggestive of pneumonia (such as consolidation, lobar or interstitial infiltrates)
  • Achieved clinical stability within 72 hours from the first antibiotic dose (clinical stability includes being off supplemental oxygen/ventilatory support and temperature remaining < 38 Celsius).

排除标准

  • (presence of ANY of the following will exclude a potential participant):
  • Hemodynamic instability at any point during hospitalization that required inotropic support
  • Requirement of respiratory support > 72 hours
  • Presence of a parapneumonic effusion >10 mm on decubitus x-ray or greater than ¼ of hemithorax opacified on chest imaging
  • Need for chest tube placement
  • Extrapulmonary involvement (ie: another infection located outside of the lungs) except for otitis media if the planned treatment is ≤ 5 days
  • Pneumonia caused by known staphylococcus aureus identified from culture (blood, bronchoalveolar aspirate, tracheal aspirate, or pleural fluid)
  • Antibiotic course started >72 hours after admission
  • Antibiotics used for > 24 hours within the 2 weeks prior to admission
  • Chronic respiratory illness other than asthma or reactive airway disease
  • Immunocompromised patient (primary or secondary)
  • Primary physician refusal
  • Parent refusal
  • Non-English speakers
  • Pregnant or lactating female
  • Participant will become ≥ 18 years old at or before the time of day 14 follow up
  • Inability to adhere to follow up

研究组 & 干预措施

Short course antibiotic duration

Experimental

The participants in this group will receive a total antibiotic course of 5 days including the number of days received during their hospital admission and following hospital admission combined.

干预措施: Ampicillin for Injection (Drug)

Short course antibiotic duration

Experimental

The participants in this group will receive a total antibiotic course of 5 days including the number of days received during their hospital admission and following hospital admission combined.

干预措施: Ceftriaxone for Injection (Drug)

Short course antibiotic duration

Experimental

The participants in this group will receive a total antibiotic course of 5 days including the number of days received during their hospital admission and following hospital admission combined.

干预措施: Amoxicillin (Drug)

Short course antibiotic duration

Experimental

The participants in this group will receive a total antibiotic course of 5 days including the number of days received during their hospital admission and following hospital admission combined.

干预措施: Ampicillin / Sulbactam Injection (Drug)

Short course antibiotic duration

Experimental

The participants in this group will receive a total antibiotic course of 5 days including the number of days received during their hospital admission and following hospital admission combined.

干预措施: Amoxicillin-clavulanate (Drug)

Short course antibiotic duration

Experimental

The participants in this group will receive a total antibiotic course of 5 days including the number of days received during their hospital admission and following hospital admission combined.

干预措施: Clindamycin (Drug)

Short course antibiotic duration

Experimental

The participants in this group will receive a total antibiotic course of 5 days including the number of days received during their hospital admission and following hospital admission combined.

干预措施: Cefprozil (Drug)

Short course antibiotic duration

Experimental

The participants in this group will receive a total antibiotic course of 5 days including the number of days received during their hospital admission and following hospital admission combined.

干预措施: Levofloxacin (Drug)

Standard of care antibiotic duration

Active Comparator

Participants will receive the standard-of-care antibiotic course in this group. That is, the duration of antibiotics will be decided by the primary treating physician in this group. The antibiotic course will include the number of days received during the participant's hospital admission and following hospital admission combined.

干预措施: Ampicillin for Injection (Drug)

Standard of care antibiotic duration

Active Comparator

Participants will receive the standard-of-care antibiotic course in this group. That is, the duration of antibiotics will be decided by the primary treating physician in this group. The antibiotic course will include the number of days received during the participant's hospital admission and following hospital admission combined.

干预措施: Ceftriaxone for Injection (Drug)

Standard of care antibiotic duration

Active Comparator

Participants will receive the standard-of-care antibiotic course in this group. That is, the duration of antibiotics will be decided by the primary treating physician in this group. The antibiotic course will include the number of days received during the participant's hospital admission and following hospital admission combined.

干预措施: Amoxicillin (Drug)

Standard of care antibiotic duration

Active Comparator

Participants will receive the standard-of-care antibiotic course in this group. That is, the duration of antibiotics will be decided by the primary treating physician in this group. The antibiotic course will include the number of days received during the participant's hospital admission and following hospital admission combined.

干预措施: Ampicillin / Sulbactam Injection (Drug)

Standard of care antibiotic duration

Active Comparator

Participants will receive the standard-of-care antibiotic course in this group. That is, the duration of antibiotics will be decided by the primary treating physician in this group. The antibiotic course will include the number of days received during the participant's hospital admission and following hospital admission combined.

干预措施: Amoxicillin-clavulanate (Drug)

Standard of care antibiotic duration

Active Comparator

Participants will receive the standard-of-care antibiotic course in this group. That is, the duration of antibiotics will be decided by the primary treating physician in this group. The antibiotic course will include the number of days received during the participant's hospital admission and following hospital admission combined.

干预措施: Clindamycin (Drug)

Standard of care antibiotic duration

Active Comparator

Participants will receive the standard-of-care antibiotic course in this group. That is, the duration of antibiotics will be decided by the primary treating physician in this group. The antibiotic course will include the number of days received during the participant's hospital admission and following hospital admission combined.

干预措施: Cefprozil (Drug)

Standard of care antibiotic duration

Active Comparator

Participants will receive the standard-of-care antibiotic course in this group. That is, the duration of antibiotics will be decided by the primary treating physician in this group. The antibiotic course will include the number of days received during the participant's hospital admission and following hospital admission combined.

干预措施: Levofloxacin (Drug)

结局指标

主要结局

Treatment failure rate

时间窗: 14 days from the first dose antibiotics

Treatment failure is defined as the clinical need for additional antibiotic treatment, an emergency department (ED) visit, or readmission to the hospital for a suspected lower respiratory tract infection within 14 days of treatment initiation.

次要结局

  • Adverse drug event rate(14 days from the first dose antibiotics)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Michelle Mitchell

Associate Professor of Pediatric Infectious Diseases

Medical College of Wisconsin

研究点 (1)

Loading locations...

相似试验